Literature DB >> 30078121

Over-the-top ACL reconstruction yields comparable outcomes to traditional ACL reconstruction in primary and revision settings: a systematic review.

Mohamed Sarraj1, Darren de Sa2, Ajaykumar Shanmugaraj3, Volker Musahl4, Bryson P Lesniak4.   

Abstract

PURPOSE: To assess clinical outcomes of over-the-top (OTT) ACL reconstruction (ACLR) in skeletally mature patients, where physeal sparing is not a consideration. The hypothesis is that OTT will produce successful yet inferior outcomes compared to anatomic ACL approaches in both primary and revision settings.
METHODS: Two reviewers searched two online databases (EMBASE and MEDLINE) from inception to October 2017 for literature on OTT ACLR in skeletally mature patients. The systematic screening process was completed in duplicate, independently, and based on predetermined criteria. An expert in the field was consulted to resolve disagreements for full-text screening. Quality assessment of included papers was performed independently and in duplicate.
RESULTS: From 3148 initial studies, 16 eligible studies (three RCTs and 13 case series) satisfied inclusion criteria. Three focused on the revision setting. The mean age of patients undergoing primary reconstruction was 26.9 ± 3.6, with 21.3% female patients and 31.4 ± 1.2 (26.1% female) in revision settings. Of primary studies reporting return to sport (n = 151), 69% of patients returned to pre-injury sports participation, with a total 94% returning to any sports activity. In revision settings (n = 48), 52.1% of patients returned to pre-injury sports participation, 25.2% returned to a lower level and 12.5% ceased sporting activity. Primary reconstruction studies reported a mean post-operative Tegner score of 6.5 ± 0.5 (n = 181) and mean KOOS of 82.8 ± 8.1 (n = 96). Primary studies reported a total 13 graft failures (3.7%), seven of which were re-ruptures (2.0%). The revision failure rate was 8.4% (four patients).
CONCLUSION: Clinically important outcomes for OTT ACLR are comparable to literature figures for traditional all-inside, transtibial and/or anteromedial portal drilling techniques. This holds true in revision settings. LEVEL OF EVIDENCE: IV.

Entities:  

Keywords:  ACL reconstruction; Anterior cruciate ligament; Non-anatomic ACL; Over-the-top

Mesh:

Year:  2018        PMID: 30078121     DOI: 10.1007/s00167-018-5084-2

Source DB:  PubMed          Journal:  Knee Surg Sports Traumatol Arthrosc        ISSN: 0942-2056            Impact factor:   4.342


  5 in total

1.  Reduction in opioid use with perioperative non-pharmacologic analgesia in total knee arthroplasty and ACL reconstruction: a systematic review.

Authors:  Ryan B Juncker; Faisal M Mirza; Joel J Gagnier
Journal:  SICOT J       Date:  2021-12-17

2.  Equivalent outcomes of ACL revision with over-the-top single and double-bundle reconstruction using hamstring tendon compared to anatomical single and double-bundle reconstruction.

Authors:  Goki Kamei; Atsuo Nakamae; Masakazu Ishikawa; Kyohei Nakata; Akinori Nekomoto; Shunya Tsuji; Naofumi Hashiguchi; Nobuo Adachi
Journal:  J Exp Orthop       Date:  2022-04-13

Review 3.  Overview of the anterolateral complex of the knee.

Authors:  Ignacio Garcia-Mansilla; Juan Pablo Zicaro; Ezequiel Fernando Martinez; Juan Astoul; Carlos Yacuzzi; Matias Costa-Paz
Journal:  World J Clin Cases       Date:  2022-08-26       Impact factor: 1.534

4.  Over-The-Top Technique for Revision ACL Reconstruction with Achilles Allograft and Associated Lateral Extra-articular Tenodesis.

Authors:  Bálint Zsidai; Ian D Engler; Oriol Pujol; Gian Andrea Lucidi; Andrew J Curley; Stefano Zaffagnini; Volker Musahl
Journal:  Arthrosc Tech       Date:  2022-09-21

5.  All-inside technique in ACL reconstruction: mid-term clinical outcomes and comparison with AM technique (Hamstrings and BpTB grafts).

Authors:  Andrea Pautasso; Marcello Capella; Luca Barberis; Luca Drocco; Riccardo Giai Via; Alessandro Bistolfi; Alessandro Massè; Luigi Sabatini
Journal:  Eur J Orthop Surg Traumatol       Date:  2020-09-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.